Renee Iacona

Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

Daphne W. Bell, Thomas J. Lynch, Sara M. Haserlat et al. · Journal of Clinical Oncology · 2005 · 607 citations

Medicine, Molecular Genetics, Oncology +17

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

José Baselga, Andrés Cervantes, Erika Martinelli et al. · Clinical Cancer Research · 2010 · 109 citations

Medicine, Oncology, Pharmacology +15

A phase II trial of gefitinib in patients with non‐metastatic hormone‐refractory prostate cancer

Eric J. Small, Joseph A. Fontana, Nizar M. Tannir et al. · British Journal of Urology · 2007 · 68 citations

Medicine, Oncology, Pharmacology +14

Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers

Josep Tabernero, Andrés Cervantes, Klaas Hoekman et al. · Journal of Clinical Oncology · 2007 · 50 citations

Medicine, Oncology, Pharmacology +15

Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis

Ray Lin, Ji Lin, Satrajit Roychoudhury et al. · Figshare · 2020 · 45 citations · Full text

Public Health, Biostatistics, Oncology +13